ダパグリフロジンプロピレングリコール水和物
ダパグリフロジンプロピレングリコール水和物 物理性質
- 融点 :
- 74 - 78°C
- 貯蔵温度 :
- -20°C Freezer
- 溶解性:
- クロロホルム(微量)、DMSO(微量)、メタノール(微量)
- 外見 :
- 個体
- 色:
- ホワイトからオフホワイト
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
絵表示(GHS) |
|
注意喚起語 |
警告 |
危険有害性情報 |
コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
![](/GHS07.jpg) |
P264, P270, P301+P312, P330, P501 |
H315 |
皮膚刺激 |
皮膚腐食性/刺激性 |
2 |
警告 |
![](/GHS07.jpg) |
P264, P280, P302+P352, P321,P332+P313, P362 |
H319 |
強い眼刺激 |
眼に対する重篤な損傷性/眼刺激 性 |
2A |
警告 |
![](/GHS07.jpg) |
P264, P280, P305+P351+P338,P337+P313P |
H335 |
呼吸器への刺激のおそれ |
特定標的臓器毒性、単回暴露; 気道刺激性 |
3 |
警告 |
![](/GHS07.jpg) |
|
|
注意書き |
P261 |
粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。 |
P280 |
保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。 |
P301+P312 |
飲み込んだ場合:気分が悪い時は医師に連絡する こと。 |
P302+P352 |
皮膚に付着した場合:多量の水と石鹸で洗うこと。 |
P305+P351+P338 |
眼に入った場合:水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。 |
|
ダパグリフロジンプロピレングリコール水和物 価格
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
ダパグリフロジンプロピレングリコール水和物 化学特性,用途語,生産方法
効能
糖尿病治療薬, SGLT-2阻害薬
商品名
フォシーガ (アストラゼネカ)
説明
Dapagliflozin propanediol monohydrate is the first approved sodium-glucose cotransporter protein 2 (SGLT2) inhibitor. It is indicated for the treatment of type 2 diabetes. When combined with diet and exercise in adults, dagliflozin helps improve glycaemic control by inhibiting glucose reabsorption in the proximal tubules of renal units and causing glycosuria. Dagliflozin can be given alone or in combination with insulin or other oral hypoglycaemic agents as adjunctive therapy.
Dagliflozin was originally approved by the FDA on 8 January 2014 for use in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It was later approved in April 2021 to reduce the risk of declining kidney function, kidney failure, cardiovascular death and hospitalisation for heart failure in adults with chronic kidney disease.
使用
Dapagliflozin Propanediol Hydrate is an SGLT2 inhibitor, which can be used for the treatment of diabetes.
定義
ChEBI: A hydrate that consists of dapagliflozin compounded with (S)-propylene glycol and hydrate in a (1:1:1) ratio. Used to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
臨床応用
The most likely process-scale synthesis has been described in a literature publication and patent, and
this is summarized in the scheme below. The synthesis began with global silylation glucolactone 63
to form tetrasiloxide 64. In parallel, commercial 5-bromo-2-chlorobenzoyl acid (65) was converted to
the corresponding acid chloride with oxalyl chloride. Subsequently, this acid chloride was subjected to
Friedel-Crafts acylation with ethyl phenyl ether (“phenetole”) in the presence of aluminum trichloride at
low temperature to give benzophenone 66 in 91% yield. Next, the carbonyl functionality within 66 was
removed upon treatment with triethylsilane and boron trifluoride-etherate, producing 5-bromo-2-chloro-
4'-ethoxydiphenylmethane 67 in 75% yield as the aglycon partner. Aryl bromide 67 was subjected to lithium halogen exchange conditions and subsequent exposure to lactone 64, which gave a mixture of
lactols which were then immediately subjected to methanesulfonic acid to provide glucol 68 in 85%
yield. The anomeric methoxy group of 68 was reduced with triethylsilane and boron trifluoride-etherate
followed by peracetylation to deliver α-C-glycoside tetra-acetate 69 in 55% (two steps) after
recrystalliaztion in ethanol. Hydrolysis of polyacetate 69 with lithium hydroxide gave dapagliflozin in
quantitative yield, and upon treatment with propanediol in water, dapagliflozin propanediol hydrate (X)
was produced.
ダパグリフロジンプロピレングリコール水和物 上流と下流の製品情報
原材料
準備製品
ダパグリフロジンプロピレングリコール水和物 生産企業
Global( 271)Suppliers
ダパグリフロジンプロピレングリコール水和物 スペクトルデータ(1HNMR)
- 960404-48-2
- Dapagliflozin (S)-Propylene Glycol Hydrate
- Dag column net a water glycol
- Dapagliflozin,(2S)-1,2-propanediol, hydrate (1:1:1)
- Dapagliflozin ((2S)-1,2-propanediol, hydrate)###461432-26-8###Dapagliflozin
- Dapagliflozin ((2S)-1,2-propanediol, hydrate)
- BMS 512148 (2S)-1,2-propanediol
- CS-1307
- Dapragliflozin Propanediol Monohydrate
- (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol compound with (2S)-1,2-Propanediol (1:1), Monohydrate (9CI)
- (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl
- Dapagliflozin Impurity 67
- BMS-512148 (2S)-1,2-propanediol, hydrate
- Enzymes Pepsase
- Dapagliflozin (API)
- (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol, compounded with (2S)-1,2-propanediol, hydrate (1:1:1)
- Dapagliflozin propanediol hydrate
- Dapagliflozin propylene glycolate hydrate
- Forxiga
- (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL COMPOUND WITH (S)-PROPANE-1,2-DIOL (1:1) HYDRATE
- (2S)-propane-1,2-diol (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol hydrate
- Dapaglilozin
- Dapagliflozin Hydrate
- Dapagliflozin Monohydrate In-House
- Dapagliflozin SC crystal
- ダパグリフロジンプロピレングリコール水和物
- ダパグリフロジンプロパンジオール
- ダパグリフロジンプロピレングリコール水和物 (JAN)